אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - esomeprazole magnesium -

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - esomeprazole magnesium, quantity: 20.7 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hyprolose; lactose monohydrate; sucrose; iron oxide red; glyceryl monostearate; polysorbate 80; povidone; light magnesium oxide; purified talc; crospovidone; pregelatinised maize starch; macrogol 400; hypromellose phthalate; maize starch; silicon dioxide; macrogol 6000; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for:,? healing of

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium -

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium -

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - esomeprazole magnesium, quantity: 41.4 mg (equivalent: esomeprazole, qty 40 mg) - tablet, enteric coated - excipient ingredients: hypromellose phthalate; sucrose; macrogol 6000; macrogol 400; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; maize starch; crospovidone; povidone; silicon dioxide; hyprolose; iron oxide red; glyceryl monostearate; polysorbate 80; light magnesium oxide; lactose monohydrate; microcrystalline cellulose; pregelatinised maize starch; titanium dioxide; hypromellose - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for:,? healing of

ארצות הברית - אנגלית - NLM (National Library of Medicine)

unit dose services - esomeprazole magnesium dihydrate (unii: 36h71644eq) (esomeprazole - unii:n3pa6559ft) - esomeprazole 40 mg - healing of erosive esophagitis esomeprazole magnesium delayed-release capsules usp are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules usp may be considered. maintenance of healing of erosive esophagitis esomeprazole magnesium delayed-release capsules usp are indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole magnesium delayed-release capsules usp are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults and children 1 year or older. esomeprazole magnesium delayed-release capsules usp are indicated for the reduction in the occurrence of gastric ulcers associated with conti

ארצות הברית - אנגלית - NLM (National Library of Medicine)

dr. reddy's laboratories inc - esomeprazole magnesium (unii: r6dxu4way9) (esomeprazole - unii:n3pa6559ft) - esomeprazole 20 mg - adults esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed ee in adults. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) for the healing of ee in pediatric patients 12 years to 17 years of age.  esomeprazole magnesium delayed-release capsules are indicated for the maintenance of healing of ee in adults. controlled studies do not extend beyond 6 months. adults esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. pediatric patients 12 years to 17 years of age esomeprazole magnesium delayed-release capsul

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: purified water; methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; hypromellose phthalate; iron oxide red; light magnesium oxide; pregelatinised maize starch; polysorbate 80; silicon dioxide; hyprolose; macrogol 6000; glyceryl monostearate; microcrystalline cellulose; povidone; macrogol 400; purified talc; maize starch; sucrose; titanium dioxide; hypromellose; iron oxide yellow - healing of duodenal ulcer associated with helicobacter pylori. ,eradication of helicobacter pylori in patients with active or healed peptic ulcers.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate -

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate -